-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

Benzinga·10/09/2026 18:11:50
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $65.